Report Preview

Behcet’s Syndrome Market

The global Behcet’s syndrome market size was valued at USD 12 million in 2021 and is projected to reach around USD 30.5 million in 2030 exhibiting a CAGR of 7% in the forecasted period. The increase in incidences of Behcets disease is expected to upsurge the market growth. Additionally, technological advances in healthcare industry and increasing R&D spending by the administration will support in creating profitable openings for important market players. However, dearth of awareness among people and healthcare specialists will act as a restriction for the growth of this market.

Main factors that boost the market growth are the growth in incidences of Behcets disease worldwide. For instance, as per the American Behcets Disease Association (ABDA) there are roughly 16,000-20,000 cases of Behcet’s disease in the U.S. and this disease is most dominant in Turkey in which almost 400 cases for each 100,000 individuals have been witnessed.

In addition, numerous major players are concentrating on the pathogenesis of the disease for the development of efficient therapeutic selections that expand results and prevent irrevocable organ damage. This, in turn, is more creating an optimistic outlook for the market. Moreover, the developing popularity of modified treatment methods for handling the disease, depending on the organs involved, the severity and period of involvement, the occurrence of attacks, gender, and the patient’s age, is also a significant growth-inducing factor.

Covid-19 had a key impact on almost all industries, such as chemical, healthcare, manufacturing, automobile, etc. But, several corporations operating in the technology sector have seen augmented revenue owing to substantial changes in consumer inclinations toward technological facilities. In addition, the disease has led to important growth in technology across emerging and developed nations. Moreover, the growth of this market is mostly driven due to the growth and progress in healthcare industry.

Type Insights

The type segment is ocular-Behcet, vasculo-Behcet, and neuro-Behcet. During the forecasted period, Neuro-Behcet are projected to grow at the fastest rate. A patient with Behcet’s disease is supposed to have neurologic symptoms and/or marks of neuro-disease Behcet’s (NBD) (BD). Related syndromes contain movement problems, cerebral venous sinus thrombosis (CVST), multiple sclerosis-like presentations, myelopathic syndrome, meningoencephalitic syndrome, and intracranial hypertension. During the forecasted period, Neuro-illness Behcet’s prevalence is possibly going to be the segment’s major driver.

Route of Administration Insights

The route of administration includes oral and injectable. The oral segment is anticipated to witness the highest CAGR during the forecasted period. For the behcet’s disease treatment the medicine is generally consumed orally which boosts the segments growth. Moreover, the injections are frequently used when the indications get worse which is barely the case as many symptoms are detected at earlier stage.

Region Insights

In 2021, North America appeared as the largest market for the global Behcet’s syndrome market, with a market share of about 42%. North America region witnessed a major share. Globally known companies like F. Hoffmann-La Roche Ltd., Pfizer Inc., 3M, and others are established in North America. The existence of such giants in the area has a substantial impact on the demand for behcet’s disease treatment services. Moreover, the market is fuelled by the growing prevalence of behcet’s disease in the region. Furthermore, immediate FDA approvals and improvements in R&D events are significant drivers of market growth for treatments for behcet’s disease.

However, Asia Pacific is expected to witness the fastest growth rate during the forecasted period. The factors that are anticipated to grow the market are increasing Behcet’s cases across the region. Moreover, Chinese people between the ages of 30-39 are most generally affected with Behcet’s illness, which has a wide medical range and can include a range of severe internal organs. In Chinese populations, men experience the condition more often and with greater severity than women.

Key Companies Insights

The market for Behcet’s syndrome is moderately competitive. With the rising applications of Behcet’s syndrome, new players are considering to enter the market. The companies are also involved in activities like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Behcet’s syndrome market, ultimately boosting the market growth. Some of the key companies working in the global Behcet’s syndrome market include:

• Creabilis Ltd.
• Cell Medica Limited
• Actelion Ltd.
• Abbott Laboratories
• Novartis AG
• Les Laboratoires
• Servier SAS
• AbbVie Inc.
• Celgene Corporation
• Hoffmann-La Roche Ltd.
• XOMA
• Mitsubishi Tanabe Pharma Corporation
• Takeda Pharmaceutical Company Limited
• Coherus BioSciences
• Servier
• Lupin Pharmaceuticals Inc.
• Other players

Some of the Recent Developments:

• In October 2022, Pfizer Inc. concluded the acquisition of Global Blood Therapeutics, Inc. (GBT) that provide expectation to underserved patient groups starting with sickle cell disease (SCD). The acquisition strengthens Pfizer’s commitment to SCD.
• In December 2021, Novartis entered into a definitive agreement to purchase the UK-based ocular gene therapy company Gyroscope Therapeutics.

Segments

By Type

• Ocular-Behcet
• Vasculo-Behcet
• Neuro-Behcet

By Route of Administration

• Oral
• Injectable

By Geography

• North America
  • S.
  • Canada
  • Mexico
• Europe
  • K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • ASEAN
• Latin America
  • Brazil
  • Argentina
  • Colombia
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt